Generic Product News (February 2017)

Pharmacy Times, February 2017 Infectious Disease, Volume 83, Issue 2

Read about the new generic products featured in February.

EZETIMIBE TABLETSMARKETED BY: Endo

COMPARE TO: Zetia (Merck)

INDICATION: Endo has announced that one of its operating companies, Par Pharmaceuticals, has begun shipment of its generic version of Merck’s Zetia. Ezetimibe is indicated for use, along with a healthy diet, to reduce elevated low-density lipoprotein cholesterol in patients with hyperlipidemia.

DOSAGE FORM: Tablets: 10 mg

FOR MORE INFORMATION: endo.com

FOSPHENYTOIN SODIUM INJECTIONMARKETED BY: Mylan

COMPARE TO: Cerebyx (Pfizer)

INDICATION: Mylan has announced the US launch of its generic version of Pfizer’s Cerebyx injection. Fosphenytoin sodium injection is indicated for the treatment of certain types of seizures.

DOSAGE FORM: Injection: 75 mg/mL

FOR MORE INFORMATION: mylan.com

SODIUM OXYBATEMARKETED BY: Jazz Pharmaceuticals

COMPARE TO: Xyrem (Jazz Pharmaceuticals)

INDICATION: The FDA has approved the first generic version of Xyrem oral solution indicated to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy. The product was approved under the Risk Evaluation and Mitigation Strategy program due to potentially serious risks.

DOSAGE FORM: Oral solution: 0.5 g/mL

FOR MORE INFORMATION: jazzpharma.com

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETSMARKETED BY: Mylan

COMPARE TO: Concerta (Janssen)

INDICATION: Mylan has announced the launch of its generic version of Janssen’s Concerta tablets. Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention-deficit/hyperactivity disorder.

DOSAGE FORM: Tablets: 18, 27, 36, and 54 mg

FOR MORE INFORMATION: mylan.com